Category Archives: 2012

Abiraterone Acetate (Zytiga) Approved to Treat Hormone-Refractory Prostate Cancer Before Chemotherapy.

In the past, when a prostate cancer patient became non-responsive (refractory) to hormonal therapy, the next step in his treatment was chemotherapy with taxotere (docetaxel). This treatment was usually accompanied by significant side effects.  Meanwhile, in April, 2011, the Food and Drug more »

Posted in 2012 | Leave a comment

Recent Information on Prostate Cancer Screening and Active Surveillance.

The National Cancer Institute (NCI) is the largest of the numerous institutes comprising the National Institutes of Health (NIH) in Bethesda and Frederick, Maryland. The NCI publishes a monthly cancer bulletin focused on all types of cancer. The current special issue (NCI more »

Posted in 2012 | Leave a comment

An Example and a Purpose For Anyone with Prostate Cancer.

At some point in life, all of us will be diagnosed with a serious and perhaps life-threatening medical condition. How will we react in such a situation? Could such an unwanted circumstance have a deeper purpose? A difficult diagnosis and illness can be viewed as either a mirror more »

Posted in 2012 | Leave a comment

Newly Diagnosed Prostate Cancer; What You Need to Know.

An extremely useful article was recently published by Nathan Roundy in the August, 2012 issue of the Prostate Cancer Research Institute (PCRI) Insights. The article is directed toward men who have been recently diagnosed with prostate cancer. It defines various more »

Posted in 2012 | Leave a comment

Identification of Localized Prostate Cancer Recurrence Using PET/CT Imaging.

It would be useful if one could detect and identify the location of localized prostate cancer recurrences and metastatic disease in early PSA recurrence in men who had previously failed initial cancer treatments. For example, such identified “focal” or local recurrences in 1-2 specific areas more »

Posted in 2012 | 4 Comments

Xtandi (Formerly MDV3100) Approved by the FDA for Treatment of Hormone- and Chemotherapy-Resistant Prostate Cancers.

On August 31st, 2012, the Food and Drug Administration (FDA) approved MDV3100 (now known as Xtandi) for treatment of prostate cancers in men who have previously failed hormone and chemo therapies. (See the full story in the August 31st issue more »

Posted in 2012 | Leave a comment

An Example of Potential New Prostate Cancer (PC) Treatments on the Horizon. Killing PC Cells With Radioactive Gold Nanoparticles Containing a Component of Tea as the Targeting Agent.

Nanotechnology is finding potential applications in many areas of our lives including cancer.  [A nanometer is defined as one billionth of a meter or one ten millionth of a centimeter (there are 2.54 centimeters per inch).] Synthetic nanometer-sized particles (such as atoms, more »

Posted in 2012 | Leave a comment

Active Surveillance May Be the Preferred Option in Some Men with Prostate Cancer.

A recent study from Johns Hopkins University School of Medicine published in the Journal of Clinical Oncology concluded that for men over 65 “active surveillance is the first option for men in this category with very-low-risk disease” according to senior investigator more »

Posted in 2012 | Leave a comment

PSA Screening Recommendations from the American Society of Clinical Oncology (ASCO).

The American Society of Clinical Oncology (ASCO) is a highly respected organization. On July 16th 2012, a committee of experts from ASCO published a provisional clinical opinion regarding PSA screening in the Journal of Clinical Oncology. This information is also summarized in more »

Posted in 2012 | Leave a comment

Treating Low-Risk, Localized Prostate Cancer Using MRI-Guided Focal Laser Therapy.

The National Cancer Institute (NCI), the largest of the institutes comprising the National Insitutes of Health (NIH) in Bethesda and Frederick, Maryland is sponsoring a clinical trial for men who have slow-growing prostate cancer confined to a small portion of the more »

Posted in 2012 | Leave a comment